论文部分内容阅读
目的研究阿托伐他汀治疗急性冠状动脉综合症的临床疗效并分析其安全性。方法将76例急性冠状动脉综合症(ACS)患者按治疗方式不同分为观察组(阿托伐他汀)和对照组(血脂康),对比治疗前后两组患者血脂水平及高敏C反应蛋白水平。结果治疗后,观察组血脂水平各指标与对照组无明显差异,P>0.05;观察组患者高敏C反应蛋白水平为(2.89±0.25)mg/L,较对照组的(4.34±0.76)mg/L低,P<0.05。两组均未出现明显不良反应。结论阿托伐他汀治疗急性冠状动脉综合症能明显降低高敏C反应蛋白水平,改善患者身体状况,且无明显副作用,安全性高,值得应用和推广。
Objective To study the clinical efficacy of atorvastatin in the treatment of acute coronary syndrome (ACS) and analyze its safety. Methods 76 patients with acute coronary syndrome (ACS) were divided into observation group (atorvastatin) and control group (Xuezhikang) according to different treatment methods. The levels of blood lipid and high-sensitivity C-reactive protein in two groups were compared before and after treatment. Results After treatment, there was no significant difference between the observation group and the control group (P> 0.05). The level of high sensitivity C-reactive protein in the observation group was (2.89 ± 0.25) mg / L compared with that of the control group (4.34 ± 0.76) mg / L low, P <0.05. No significant adverse reactions occurred in both groups. Conclusion Atorvastatin treatment of acute coronary syndrome can significantly reduce high-sensitivity C-reactive protein levels and improve the patient’s physical condition, and no obvious side effects, high safety, it is worth to apply and promote.